Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date
NonAdvSM PDUFA target action date
Cash balance of
“With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST,” said
Business Highlights
- Plan to present multiple posters featuring bezuclastinib at the 68th Annual Meeting of the
American Society of Hematology (ASH) being heldDecember 12-15, 2026 , inNew Orleans . Featured results will highlight more detailed analyses from the SUMMIT trial of bezuclastinib’s effects on skin and neurocognitive symptoms, longer term pathobiology follow-up and an MS2D2 symptomatic comparison of symptom burden in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients before and after bezuclastinib treatment with that of the general population. Included in these presentations will be the first look at clinical results from the SUMMIT sub-study, investigating the patient benefit of switching from avapritinib to bezuclastinib. - Announced the initiation of a single-arm, 40 patient extension cohort of the PEAK trial investigating the safety and efficacy of bezuclastinib in combination with sunitinib in first-line GIST patients. This cohort is designed to prospectively measure ORR and PFS in patients with either exon 9 or exon 11 primary mutations.
- Announced the
U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).
Anticipated Upcoming Milestones
- Potential FDA approval of bezuclastinib in GIST – PDUFA date of
November 30, 2026 - Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of
December 30, 2026 - Potential FDA approval of bezuclastinib in AdvSM – PDUFA date of
June 29, 2027 - Investigational New Drug (IND) applications to be submitted for CGT1815, Cogent’s novel, selective pan-KRAS(ON) inhibitor, and CGT1145, Cogent’s novel, selective JAK2 V617F inhibitor in Q4 2026
- Complete dose escalation for CGT4255, Cogent’s CNS-penetrant, selective mutant ErbB2 inhibitor
Upcoming Investor Conferences
Guggenheim Healthcare Innovation Conference onNovember 10 at7:30 am ET UBS Global Biopharma Conference onNovember 17 at12:00 pm GMT (7:00 am ET )Jefferies Global Healthcare Conference onNovember 17 at5:00 pm GMT (12:00 pm ET )Piper Sandler Healthcare Conference onDecember 1 at11:00 am ET
The live webcasts can be accessed on the Investors & Media page of Cogent’s website at investors.cogentbio.com/events. A replay will be available approximately two hours after completion of each event and will be archived for up to 30 days.
Third Quarter 2026 Financial Results
Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Net Loss: Net loss was
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Ka, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: potential FDA approval and commercial launch of bezuclastinib in GIST; potential FDA approval of bezuclastinib in both NonAdvSM and AdvSM; cash runway expected to fund operations into late 2028 and well past all three pending PDUFA action dates for bezuclastinib; plans to submit INDs for the company’s JAK2 and KRAS pipeline programs and to move into clinical development soon; plans to complete dose escalation for CGT4255; and plans to present multiple poster presentations featuring bezuclastinib at ASH 2026 and the contents of those presentations. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 75,099 | $ | 68,989 | $ | 221,275 | $ | 194,221 | |||||||
| General and administrative | 42,085 | 14,366 | 102,154 | 39,649 | |||||||||||
| Total operating expenses | 117,184 | 83,355 | 323,429 | 233,870 | |||||||||||
| Loss from operations | (117,184 | ) | (83,355 | ) | (323,429 | ) | (233,870 | ) | |||||||
| Other income: | |||||||||||||||
| Interest income | 7,052 | 3,887 | 22,121 | 9,212 | |||||||||||
| Interest expense | (1,243 | ) | (1,459 | ) | (3,673 | ) | (1,773 | ) | |||||||
| Other expense, net | (51 | ) | (3 | ) | (202 | ) | (14 | ) | |||||||
| Total other income, net | 5,758 | 2,425 | 18,246 | 7,425 | |||||||||||
| Net loss | $ | (111,426 | ) | $ | (80,930 | ) | $ | (305,183 | ) | $ | (226,445 | ) | |||
| SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA | ||||||||
| (in thousands) | ||||||||
| (unaudited) | ||||||||
| 2026 | 2025 | |||||||
| Cash, cash equivalents and marketable securities | $ | 791,134 | $ | 900,765 | ||||
| Working capital | $ | 730,466 | $ | 846,402 | ||||
| Total assets | $ | 832,142 | $ | 937,607 | ||||
| Total liabilities | $ | 315,884 | $ | 301,236 | ||||
| Total stockholders’ equity | $ | 516,258 | $ | 636,371 | ||||

Contact:Source:Christi Waarich Senior Director, Investor Relationschristi.waarich@cogentbio.com617-830-1653
